| 1 |
26490659 | Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy? | 2015 Oct 21 |
1 |
| 2 |
25474278 | Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy. | 2014 Dec |
1 |
| 3 |
20530421 | Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance. | 2010 Apr |
1 |
| 4 |
19155291 | Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence. | 2009 Feb 1 |
1 |
| 5 |
11431359 | Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. | 2001 Jul 1 |
1 |
| 6 |
9635719 | The effect of activation of wild-type p53 function on fluoropyrimidine-mediated radiosensitization. | 1998 Jun 1 |
1 |